Day 5 Track 2

Change is the Only Constant: The 2021 Regulatory “Level Set” in the Sprint to Value-Based Care

Tynan O. Kugler, Principal, PYA, P.C.
Adria Warren, Partner, Foley & Lardner, LLP

A major overhaul of the Stark Law and Anti-Kickback Statute in 2021 has introduced new flexibilities to encourage innovative value-based arrangements and further the government’s goals of improved quality outcomes, health system efficiencies, and lower costs. This presentation will address key highlights of the regulatory framework under the final rules and provide practical tips and considerations applicable to structuring, valuing, and implementing oncology transactions.

The Next Wave in Oncology Transactions

This session is sponsored by Alliance Oncology

Curtis Bernstein, CPA/ABV, CVA, ASA, CHFP, MBA, Principal, Pinnacle Healthcare Consulting
Josh Eaves, Senior Vice President, Strategic Partnerships and Acquisitions, Alliance Oncology
Brad Prechtl, MBA, Chief Executive Officer, American Oncology Network, LLC
Adria Warren, Partner, Foley & Lardner, LLP

Providers across the country are exploring ways to leverage emerging opportunities in value-based care, whether independently, with hospitals, or as part of a “value-based arrangement” as recently defined by CMS. Join us to explore the newest trends and learn about opportunities and business models available to community providers and hospitals in oncology transactions.

Understanding Antitrust and Oncology

Holden Brooks, Partner, Foley & Lardner, LLP
Michael Diaz, MD, Assistant Managing Physician, Florida Cancer Specialists and Research Institute; Director of Patient Advocacy, Florida Society of Clinical Oncology; Former President, Community Oncology Alliance
Barbara L. McAneny, MD, Chief Executive Officer, New Mexico Oncology and Hematology Consultants; Former President, American Medical Association

The competitive landscape in oncology has been in flux for many years, with community-based practices and individual physicians deciding to join or affiliate with hospital-based systems in increasing numbers. Understanding antitrust concepts has never been more important in the oncology space. In these conversations, we will explore how to think of recent developments in the business of oncology through the lens of antitrust and also provide basic guidance around antitrust compliance, drawing on the broad industry perspective and practical experience of the panelists.